Drug news
FDA Advisory Committee recommends mirabegron(Astellas)for treatment of Overactive Bladder
Astellas Pharma Inc. has announced that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted that the overall risk/benefit assessment supports approval of mirabegron (YM178) for the treatment of Overactive Bladder (OAB) (Yes: 7, No: 4, Abstain: 1).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins